Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DIA Regimen Versus IA Regimen for Induction Therapy in Younger Adults With Acute Myeloid Leukemia: A Multicenter Open-Label Randomized Controlled Trial.

American journal of hematology·2025
Same author

Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study.

Therapeutic advances in hematology·2024
Same author

Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review.

Annals of hematology·2023
Same author

Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review.

Medicine·2023
Same author

Clinical profile, etiology, and outcome of hemophagocytic lymphohistiocytosis associated with histiocytic necrotizing lymphadenitis.

World journal of pediatrics : WJP·2023
Same author

Identification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line.

BioMed research international·2017

Related Experiment Video

Updated: Jan 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Daratumumab for CD20-CD38+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

ZeTong Hong1, ZhaoYang Hong2, YaXian Ma1

  • 1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.

Journal of Cellular and Molecular Medicine
|October 17, 2025
PubMed
Summary

Daratumumab offers a promising treatment for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients with CD20-CD38+ expression, showing good remission rates and aiding CAR-T therapy transitions.

Keywords:
CAR‐T therapyCD20CD38chemotherapyimmunotherapy

More Related Videos

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.6K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K

Related Experiment Videos

Last Updated: Jan 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

2.6K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients often exhibit reduced CD20 expression after rituximab treatment.
  • Targeted therapy replacement is crucial for R/R DLBCL treatment.
  • CD38 expression in R/R DLBCL warrants investigation for alternative therapeutic targets.

Purpose of the Study:

  • To evaluate Daratumumab as a monotherapy or combination chemotherapy for CD20-CD38+ R/R DLBCL patients.
  • To assess Daratumumab's efficacy in patients who failed prior CD20-targeted treatments.
  • To determine Daratumumab's adjuvant effect on subsequent CAR-T (chimeric antigen receptor T-cell immunotherapy).

Main Methods:

  • Retrospective analysis of four CD20-CD38+ R/R DLBCL patients treated with Daratumumab-based combination chemotherapy.
  • Subsequent CAR-T therapy for eligible patients.
  • Construction of allografted tumor models in mice for evaluation.

Main Results:

  • Four patients achieved varying remission degrees: 2 complete remissions (CR), 1 partial remission (PR), and 1 stable disease (SD).
  • One-year overall survival (OS) rate was 75%, 1-year progression-free survival (PFS) rate was 50%, and median OS (mOS) was 12 months.
  • Adverse effects were moderate and reversible; two patients successfully transitioned to CAR-T therapy with manageable grade 1 cytokine release syndrome (CRS).

Conclusions:

  • Daratumumab combination therapy shows significant potential for treating CD20-CD38+ R/R DLBCL.
  • Daratumumab serves as a viable bridge therapy for subsequent CAR-T treatment.
  • This approach offers a promising alternative for R/R DLBCL patients with reduced CD20 expression.